

## PERIMORTEM CESAREAN SECTION

When maternal cardiac arrest occurs before 24 weeks of gestation, the purpose of cardiopulmonary resuscitation (CPR) is to resuscitate the mother. If she is resuscitated, it is likely that pregnancy will proceed. Emergency delivery of the fetus is not likely to improve the maternal chances of survival. In contrast, at or beyond 24 weeks of gestation, delivery of the fetus may actually improve maternal survival by decreasing aorto-caval compression with a consequent improvement of venous return and cardiac output. In addition, chest compression will be more effective once the gravid uterus is evacuated, and the functional residual capacity of the lung will increase with a consequent increase of maternal oxygenation and resuscitation efforts<sup>1,2</sup>.

During the tragic years of Lebanon 1975-1990<sup>3</sup>, a large number of casualties resulted in serious head injuries; one fifth of all casualty admissions to the American University of Beirut Medical Center was patients with skull injuries associated with penetrating brain damage. Craniotomy when feasible, was found preferable to the accepted technique of craniectomy. The level of consciousness has an important bearing on prognosis<sup>4</sup>. In the seriously head-injured pregnant victims, perimortum Cesarean delivery of the near or the full-term fetus was attempted in order to save the fetus.

Perimortum Cesarean section may be indicated to save both the mother and the fetus during certain catastrophic complications such as anaphylactic reactions associated with anesthesia<sup>5</sup>. The placenta plays an important role in protecting the fetus against drug-induced anaphylactic reactions in the parturient. The placental barrier will prevent crossing of the high molecular weight IgE antibodies from the mother to the fetus. Also, the high diamine oxidase of the maternal decidua will catalyse the oxidative deamination of histamine and other related endogenous amines released during anaphylaxis. Emergency Cesarean section can save the fetus, and provide optional conditions for saving the mother<sup>5</sup>.

Emergency delivery of the fetus by Cesarean section can also optimize the hemodynamics in the pregnant cardiac patients presenting after cardiopulmonary bypass (CPB) with refractory hemodynamic deterioration and/or persistent fetal distress. It may be also advisable to consider Cesarean section before CPB if the gestational age is greater than 28 weeks and fetal maturity is reached, in order to maximize the chances of favorable maternal and fetal outcome<sup>6</sup>.

In conclusion, these three case reports show that perimortem Cesarean delivery can save the fetus, and may optimize the conditions for saving the mother. The first case report shows that perimortem Cesarean section in a patient with irreversible head injury saved the newborn,

but not the mother. In the second pregnant patient who suffered from cardiac arrest secondary to anaphylactic reaction, perimortem Cesarean section saved the fetus, and optimized the conditions for successful resuscitation of the mother. In the third cardiac patient undergoing CPB, Cesarean delivery of the fetus

facilitated successful weaning from CPB.

Anis Baraka, MD, FRCA (Hon)  
Emeritus Professor of Anesthesiology  
American University of Beirut  
Beirut - LEBANON

## References

1. ALIA DABBOUS, FOUAD SOUKI: Cardiac arrest in pregnancy. *MEJ Anesth*; 2007, (19 92):449-468.
2. KATZ VL, DOTTERSI DJ, ET AL: Perimortom Cesarean Delivery. *Obstet Gynecol*; 1986, 68:571.
3. ANIS BARAKA: Anesthetic problems during the tragic war in Lebanon. *MEJ Anesth*; 1983, 7 (1&2):41053.
4. FUAD SAMI HADDAD: Nature and management of penetrating head injuries during the civil war in Lebanon. *MEJ Anesth*; 1983, 7 (1&2):59-75.
5. ANIS BARAKA, SAMIA SFEIR: Anaphylactic cardiac arrest in a parturient. Response of the newborn. *JAMA*; 1980, 243:1745.
6. BARAKA A, KAWKABANI N, HAROUN S: Hemodynamic deterioration following cardiopulmonary bypass during pregnancy. Resuscitation by post-operative emergency Cesarean section. *J Cardiothoracic and Vascular Anesthesia*; 2000, 14, no. 3: 314-315.



bridion<sup>®</sup>  
sugammadex

Predictable. Complete. Rapid.

## BRIDION—for optimal neuromuscular blockade management and improved recovery

### Predictable and complete reversal

- 98% of BRIDION patients recovered to a TOF<sup>\*</sup> ratio of 0.9 from reappearance of T<sub>2</sub><sup>†</sup> within 5 minutes<sup>2</sup>
- 97% of BRIDION patients recovered to a TOF<sup>\*</sup> ratio of 0.9 from 1 to 2 PTCs<sup>†</sup> within 5 minutes<sup>3</sup>

### Rapid reversal

- BRIDION rapidly reversed patients from reappearance of T<sub>2</sub><sup>†</sup> in 1.4 minutes<sup>2</sup>
- BRIDION rapidly reversed patients from 1 to 2 PTCs<sup>†</sup> in 2.7 minutes<sup>3</sup>

**BRIDION is indicated for the reversal of neuromuscular blockade induced by rocuronium or vecuronium. In children and adolescents (aged 2-17 years), BRIDION is only recommended for routine reversal of moderate rocuronium-induced neuromuscular blockade<sup>1</sup>**

#### Important safety information

BRIDION is not recommended in patients with severe renal impairment. Studies in patients with hepatic impairment have not been conducted and, therefore, patients with severe hepatic impairment should be treated with great caution. Caution should be exercised when administering BRIDION to pregnant women as no clinical data on exposed pregnancies are available.

BRIDION has not been investigated in patients receiving rocuronium or vecuronium in the Intensive Care Unit (ICU) setting.

If neuromuscular blockade is required within 24 hours of BRIDION administration, a nonsteroidal neuromuscular blocking agent should be used instead of rocuronium or vecuronium. The most commonly reported adverse reactions were dysgeusia (metal or bitter taste) and anesthetic complications (movement, coughing, grimacing, or suckling on the endotracheal tube). In patients treated with BRIDION, a few cases of awareness were reported. The relation to BRIDION was uncertain. In a few individuals, allergic-like reactions (i.e., flushing, erythematous rash) following BRIDION were reported. Clinicians should be prepared for the possibility of allergic reactions and take the necessary precautions. In a trial of patients with a history of pulmonary complications, bronchospasm was reported in 2 patients and a causal relationship could not be fully excluded. Volunteer studies have demonstrated a slight (17%-22%) and transient (<30 minutes) prolongation of the prothrombin time/activated partial thromboplastin time (PT/aPTT) with BRIDION; however, clinical studies have demonstrated no clinically relevant effect on peri- or postoperative bleeding complications with BRIDION alone or in combination with anticoagulants. As BRIDION has demonstrated an in vitro pharmacodynamic interaction with anticoagulants, caution should be exercised in patients on anticoagulation for a pre-existing or comorbid condition. This pharmacodynamic interaction is not clinically relevant for patients receiving routine postoperative prophylactic anticoagulation. Although formal interaction studies have not been conducted, no drug interactions were observed in clinical trials. Preclinical data suggest that clinically significant drug interactions are unlikely with the possible exceptions of toremifene, fusidic acid, and hormonal contraceptives.

<sup>\*</sup> Train-of-four  
<sup>†</sup> Post tetanic counts  
<sup>‡</sup> Second twitch

REFERENCES: 1. BRIDION Summary of Product Characteristics (SPC). 2. Blobner M, Eriksson LI, Scholz J, Motsch J, Della Rocca G, Prins ME. Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. [published online ahead of print July 30, 2010]. *Eur J Anaesthesiol*. doi:10.1097/EJA.0b013e32833d5eb7. 3. Jones RK, Caldwell JE, Brill SJ, Soto RG. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. *Anesthesiology*. 2008;109(5):816-824.


Please see summary of product characteristics for full prescribing information.



Copyright © 2010 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA. All rights reserved. 05-2013-BRID-2011-LEVANT-1196-J

**PAJUNK®**

Pioneering Medical Tehnology



**TAP Block And InfiltraLong**  
For Effective Treatment  
Of Long And Deep Incisions

### **Sono Cannulas**

For Single Shot UltraSound  
Guided Nerve Blocks



### **SonoSystem And SonoLong Curl**

For UltraSound Guided Nerve Blocks



### **Sprotte® 2.G**

The New Generation  
Dura Puncture In Minimum Time



### **SonoEye Ophtalmic Block**

For Peribulbar And Retrobulbar  
Blocks Under Ultrasonic Monitoring



LMA™  
Better by Design

Question.

Your patient requires urgent pain medication. How can you administer this less invasively?

Answer.



LMA MAD Nasal™  
Needle-free intranasal drug delivery device

Atomization spray

The spray atomizes drugs into a fine mist of particles 30-100 microns in size.<sup>1</sup>

Malleable stylet

The malleable stylet allows 180° positioning of the nasal plug.

Accurate dosing


The syringe enables the accurate measurement of drugs to be delivered.

Pressure

High applied pressure ensures that drugs are atomized into a fine mist of particles through the tip of the plug.

Soft conical plug

The plug forms a seal with the nostril preventing expulsion of fluid.



Spray geometry

Spray cone with a wide 62.75° average spray angle and a 36.9mm average plume width.<sup>1</sup>

References:

1. Talon M. et al., J Burn Care Research 2009; 30: 599-605.
2. MAD (Mucosal Atomization Device) Medical Atomizer In Vitro Spray Characterization, 2011



**It's like flying business class  
and paying coach fare.**



In an uncertain world where perioperative care is increasingly complex, uptime is critical. GE's anesthesia portfolio is known for dependable quality and a commitment to reliable performance that helps reduce operational costs long after the point of purchase. Today, GE Healthcare is changing the game and redefining affordable performance for the masses. No compromises. No boundaries.

Carestation 600 Series...It's all within reach.

[gehealthcare.com](http://gehealthcare.com)

© 2015 General Electric Company - All rights reserved.  
GE and GE Monogram are trademarks of General Electric Company.  
JB28064XX

Exclusive Dealer

**C.M.M.** S.A.R.L.  
SUPPLIES & SERVICES

[www.cmm\\_lb.com](http://www.cmm_lb.com)

Vanlian Center, Fuad Chehab Ave. Sin El Fil, Beirut, Lebanon

P.O.Box: 166804 T:+961 (0)1 512 820 +961 (0)1 512 821

M:+961 70 101 740 F:+961 (0)1 512 822